Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 | ||
By: PR Newswire Association LLC. - 12 Mar 2024 | Back to overview list |
|
DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support further development of zanidatamab as a treatment for biliary tract cancer (BTC), gastroesophageal adenocarcinoma (GEA) and breast cancer. External key opinion leaders in GEA and breast cancer will also discuss current treatment paradigms and unmet needs for those cancers, and how zanidatamab may provide a new treatment option for patients. Audio webcast/conference call: Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. About Jazz Pharmaceuticals Contacts: Jazz Investor Contact: Jazz Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-host-virtual-zanidatamab-rd-day-on-tuesday-march-19-2024-302087115.html SOURCE Jazz Pharmaceuticals plc |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |